IPO TABLE: Five biotech offerings coming soon after Affimed priced, eight others filed or set terms
This article was originally published in Scrip
Executive Summary
The market for initial public offerings has been especially frothy for biotechnology companies during the past two years and the week of 15 to 19 September may illustrate perfectly the strange dichotomy at work in the IPO space.
You may also be interested in...
Bluebird’s Zynteglo Launch Under Way, But First Revenue Will Take Months
Bluebird bio will not see revenue for Zynteglo until it is infused into beta-thalassemia patients, which will take months due to the ex vivo gene therapy’s complex manufacturing and quality control process.
Bluebird’s Zynteglo Approval Kicks Off Commercial Operations
Bluebird bio’s Tom Klima told Scrip launch preparations are well under way, including negotiations with payers on outcomes-based reimbursement agreements.
Finance Watch: The Job Cuts Keep Coming As Companies Try To Conserve Cash
Restructuring Updates: Homology implemented modest job cuts as it ended a gene therapy trial, while ProQR revealed its second round of layoffs this year and Synthetic Biologics shifted focus to oncolytic virus pipeline. Also, Bolt, MacroGenics and others deprioritized programs in their Q2 updates.